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Abstract
Background: Older patients with newly diagnosed type 2 diabetes mellitus are less likely to receive
antihyperglycaemic therapy compared to their younger counterparts. The purpose of this study was to assess the
reasons of general practitioners (GPs) for not treating younger and older patients with newly diagnosed type 2
diabetes mellitus with antihyperglycaemic agents.
Methods: In a survey conducted between November 2009 and January 2010, 358 GPs from the United Kingdom
selected reasons for not initiating antihyperglycaemic therapy in younger (< 65 years) and older (≥65 years)
patients with newly diagnosed type 2 diabetes mellitus and untreated with any antihyperglycaemic agent for at
least six months following diagnosis. Thirty-six potential reasons were classified into four major categories: Mild
hyperglycaemia, Factors related to antihyperglycaemic agents, Comorbidities and polypharmacy, and Patient-related
reasons. Reasons for non-treatment were compared between younger (n = 1, 023) and older (n = 1, 005) patients.
Results: Non-treatment reasons related to Mild hyperglycaemia were selected more often by GPs for both younger
(88%) and older (86%) patients than those in other categories. For older patients, Factors related to
antihyperglycaemic agents (46% vs. 38%) and Comorbidities and polypharmacy (33% vs. 19%), both including safety-
related issues, were selected significantly (p < 0.001) more often by GPs. No between-group difference was
observed for the Patient-related reasons category. The GP-reported HbA1c threshold for initiating antihyperglycaemic
therapy was significantly (p < 0.001) lower for younger patients (mean ± standard deviation: 7.3% ± 0.7) compared
to older patients (7.5% ± 0.9).
Conclusions: GPs selected reasons related to Mild hyperglycaemia for non-treatment of their untreated patients
with newly diagnosed type 2 diabetes mellitus, despite nearly one-third of these patients having their most recent
HbA1c value ≥7%. The findings further suggest that safety-related issues may influence the non-treatment of older
patients with type 2 diabetes mellitus.
Background
In 2009, the prevalence of diabetes was 4% in the United
Kingdom (UK), with the number of people diagnosed with
diabetes increasing from 1.4 million in 1996 to 2.6 million
[1]. This estimate is projected to reach 4 million by 2025.
Most of these patients will be diagnosed with type 2
diabetes mellitus due to the increasing population of older
adults and prevalence of obesity. At the time of diagnosis
of type 2 diabetes mellitus, initiating treatment with
metformin along with lifestyle changes is recommended
for most adults without special considerations for older
people [2]. NICE (National Institute of Health and Clinical
Excellence) recommends initiating metformin therapy in
UK patients with type 2 diabetes mellitus after a period of
lifestyle modification [3].
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diabetes mellitus remain untreated with antihyperglycae-
mic agents despite having inadequate glycaemic control
[4-7]. Some studies have shown that older patients with
newly diagnosed type 2 diabetes mellitus are less likely to
receive antihyperglycaemic therapy [8,9]. Furthermore,
although older patients appear to have improved thera-
peutic outcomes if antihyperglycaemic therapy is intensi-
fied compared to younger patients, younger patients are
more likely to receive therapy intensification [10]. Others
have reported that age does not influence the initiation
or intensification of antihyperglycaemic therapy [4,11].
Nonetheless, delayed treatment initiation or intensifica-
tion may have significant negative outcomes for older
patients who typically present with greater medical
comorbidity and vulnerability to untreated hyperglycae-
mia. Therefore, it was important to understand the rea-
sons of general practitioners (GPs) for not treating
younger (< 65 years) and older (≥65 years) patients with
newly diagnosed type 2 diabetes mellitus with antihyper-
glycaemic agents.
Methods
Physician and Patient Selection and Data Collection
A survey was conducted in a sample of GPs from the UK
between November 2009 and January 2010. GPs treating
patients with type 2 diabetes mellitus in usual care settings
across the UK were the primary target group. The GPs
originated from the Kantar Health Physician Panel con-
taining over 6, 000 GPs from which a random sample was
invited to take part in the survey. All participating physi-
cians had to fulfill the following screening criteria in order
to be eligible to take the survey: specialty being general
practice, at least two years in practice, at least 50% of pro-
fessional time spent on direct patient care, be primarily
responsible for the diabetes management of at least ten
patients per month, and had no participation in a physi-
cian’s panel activity in the last two months.
Additionally, the GPs must have available patient
records of at least one patient from each age category (<
65 or ≥65 years at the time of type 2 diabetes mellitus
diagnosis). Each eligible and participating GP provided
data from chart review for individual patients who met the
following inclusion criteria: at least 18 years of age at time
of type 2 diabetes mellitus diagnosis, received no treat-
ment with antihyperglycaemic agents for at least six
months following diagnosis and also remained untreated
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visit for management of their diabetes within the six
months prior to the survey. The six-month time period
following diagnosis was selected to allow for recom-
mended lifestyle interventions as initial treatments. GPs
were requested to provide results for younger (< 65 years)
and older (≥65 years) patients in a 1:1 ratio. GPs could
provide results for more than one pair of younger and
older patients. The following data were extracted from the
patient’s charts: demographics, comorbidities, medication
use, laboratory measurements, and vital signs. HbA1c and
fasting blood glucose data were collected at the time clo-
sest to diagnosis and time closest to the survey date (i.e.,
most recent laboratory measurements). Remaining data
were collected only at the time closest to the survey date
(lipid levels, serum creatinine, estimated glomerular filtra-
tion rate, height, weight, and blood pressure). Body mass
index was calculated as weight in kilograms divided by
squared height in meters. GPs provided relevant patient
data via the internet using an electronic data capture form.
The target patient sample size was 2, 000 patients, with 1,
000 each for younger and older patients. Approximately 4,
000 GPs were invited to participate. Of the 669 respon-
dents who passed the initial screening questions, 571 GPs
were considered eligible to participate. Of the eligible GPs,
358 participated and completed the survey and provided
select patient results before the planned sample size was
achieved.
According to the guidelines developed by the
National Research Ethics Service (NRES: http://www.
nres.npsa.nhs.uk/applications/guidance/research-gui-
dance/?entryid62=66984), the present study did not
require Research Ethics Committee review for the fol-
lowing reasons: it was a non-randomized physician
survey including a brief retrospective chart review con-
ducted by the participating physicians and did not
involve any contact with patients or interventions.
Furthermore, patients and participating physicians
were both completely de-identified in data collection
and analysis.
General Practitioners’ Reasons for Non-treatment
The survey was developed based on extensive interviews
with an expert panel of practicing physicians and academic
researchers. Interviews included discussions on treating
older versus younger patients and scenarios where patients
are not treated with antihyperglycaemic agents for at least
six months after initial diabetes diagnosis and potential
reasons relevant to non-treatment with antihyperglycae-
mic agents. After the survey was drafted according to the
experts’ opinions, it was presented back to the experts for
review and approval. A comprehensive list of 36 possible
reasons for non-treatment with antihyperglycaemic agents
was compiled. The 36 reasons were grouped into four
high-level categories: Mild hyperglycaemia (three items),
Factors related to antihyperglycaemic agents (eighteen
items), Comorbidities and polypharmacy (five items), and
Patient-related reasons (ten items). The list was provided
to GPs using an electronic data capture form. GPs selected
all applicable reasons why their patients had not been trea-
ted with antihyperglycaemic agents after diagnosis, and
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tion, the GPs were asked to provide an HbA1c threshold
value for initiating antihyperglycaemic therapy for each
patient.
Statistical analyses
Descriptive statistics were used to summarise patient
demographics, disease characteristics, and reasons for
non-treatment with antihyperglycaemic agents. Reasons
for non-treatment were evaluated based on all reported
reasons (all-reasons analyses) and the first-ranked reason
(first-ranked reasons analyses). The between-age group
comparisons were analyzed with t-tests or nonparametric
tests for continuous data and c
2 test for categorical data.
Results
Patient Characteristics
GPs provided data for 2, 028 patients who were newly
diagnosed with type 2 diabetes mellitus and also untreated
with antihyperglycaemic therapy for at least six months
following diagnosis: 1, 023 younger patients (< 65 yrs;
mean age at diagnosis = 48.2 years) and 1, 005 older
patients (≥65 years; mean age at diagnosis = 70.1 years)
(Table 1). Compared with younger patients, older patients
had a longer duration of type 2 diabetes mellitus (i.e., time
from first diagnosis of type 2 diabetes mellitus to the sur-
vey date), a lower body mass index, and higher prevalence
of cardiovascular conditions and microvascular complica-
tions (especially renal disease) and were taking a greater
number of medications (all p < 0.001; Table 1). A higher
proportion of younger patients was male and lived inde-
pendently (Table 1). Measurements related to glycaemic
control did not differ between age groups (Table 1).
Although HbA1c tended to decline from baseline (i.e., dif-
ference between measurement closest to diagnosis and
most recent measurement) in both groups, the proportion
of patients with their most recent measure of HbA1c ≥7%
was approximately 31% and not different between younger
and older patients (Table 1).
Survey Results
Collectively, reasons within the Mild hyperglycaemia cate-
gory were chosen more frequently relative to those in the
other categories by GPs as reasons for non-treatment in
both age groups, with no significant differences between
age groups in the all-reasons analysis (Table 2). Factors
related to antihyperglycaemic agents were selected more
often (p < 0.001) for older patients compared with younger
patients. Within this category, numerous individual rea-
sons accounted for the between-group difference including
some related to side effects (e.g., hypoglycaemia, fluid
retention, and fracture) and others related to the cognitive
or physical function of the patient (Table 2). Reasons
related to Comorbidities and polypharmacy were also
selected significantly more often (p < 0.001) for older
patients. Within this category, disease or medication
burdens and factors related to polypharmacy (side effects
or drug-drug interactions) were selected as reasons with
greater frequency in the older patients. No differences
overall were observed in the Patient-related reasons cate-
gory. However within this category, fear of weight gain
was chosen by GPs more often for younger patients,
whereas non-significant trends were observed for more
GPs selecting fear of hypoglycaemia and physical difficulty
in taking medications as reasons for non-treatment in
older patients (Table 2).
In an analysis using only first-ranked reasons, no signifi-
cant differences within the high-level reasons categories
were observed between age groups. With age groups com-
bined, the overall percentage of GPs selecting reasons
within the Mild hyperglycaemia category as the first-
ranked reason was 79% followed by Patient-related reasons
(14%), Comorbidities and polypharmacy (4%) and Factors
related to antihyperglycaemic agents (3%). The GPs’ first-
ranked reasons for non-treatment were also evaluated by
category and most recent HbA1c stratum. HbA1c level was
associated with selecting reasons within Mild hyperglycae-
mia category (Figure 1). GPs selected reasons within Mild
hyperglycaemia category for 29% of their patients who had
an HbA1c ≥7%.
GP-reported HbA1c threshold for initiating an
antihyperglycaemic agent
GP-reported HbA1c threshold for initiating antihypergly-
caemic therapy was significantly (p < 0.001) lower for
younger patients (mean ± standard deviation: 7.3% ± 0.7)
compared to older patients (7.5% ± 0.9). The proportion
of patients with their most recent HbA1c measurement
above their GP-reported HbA1c threshold was significantly
higher (p = 0.002) in the younger patients (14.3%) com-
pared to the older patients (10.4%).
Discussion
T h i ss t u d ya s s e s s e dt h er e a s o n sr e p o r t e db yas a m p l eo f
UK GPs for not initiating antihyperglycaemic therapy in
younger (< 65 years) and older (≥65 years) patients with
newly diagnosed type 2 diabetes mellitus who remained
untreated for at least six months following the initial
diagnosis. In patients whose HbA1c was well controlled at
the time of the survey, the GPs reason for not initiating
treatment was often that the patients had only Mild
hyperglycaemia, whereas for less well-controlled patients,
other reasons were more prominent. Interestingly, 29%
of patients had an HbA1c ≥7% despite their GP’s selection
of the first-ranked reason being Mild hyperglycaemia.I n
a cross-sectional survey study of US-based practices, phy-
sicians provided reasons of “improving/doing well” for
over 50% of the patients who had an HbA1c ≥7% and no
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after a recent office visit [12]. These findings represent an
important gap between treatment guidelines and the cur-
rent clinical practice.
GPs were also requested to provide an HbA1c threshold
for initiating antihyperglycaemic therapy for individual
patients included in this study. The mean for the GP-
reported HbA1c threshold for initiating antihyperglycae-
mic therapy was lower for younger patients than for
older patients (7.3% vs. 7.5%). This lower threshold for
younger patients may explain why a higher proportion of
younger patients (14%) had their most recent HbA1c
value exceed their GP-defined individualized threshold
for initiating treatment than that of the older patients
(10%). Interestingly, the GP-reported thresholds on aver-
age were near the HbA1c value of 7.5%, which was
recently associated with the lowest incidence of all-cause
mortality and progression to macrovascular events [13].
NICE recommends treatment targets between 6.5% and
7.5% depending on the extent of pre-existing comorbid
conditions and agreement with the patient [3]. However,
GPs actually applied an HbA1c threshold ≥7.5% for initi-
ating antihyperglycaemic therapy in about half of these
older patients.
Table 1 Characteristics of patients provided by the general practitioners
Patients
< 65 years
(n = 1, 023)
Patients
≥ 65 years
(n = 1, 005)
p-value
Demographics
Age at survey, years 50.7 ± 9.2 74.1 ± 7.3 < 0.001
Male 61 54 0.001
Body mass index, kg/m
2 31.2 ± 6.4 28.9 ± 5.4 < 0.001
Diabetes-related characteristics
Age at diabetes diagnosis, years 48.2 ± 9.2 70.1 ± 8.5 –
Duration of diabetes*, months 18 (9, 36) 25 (11, 60) < 0.001
HbA1c closest to diabetes diagnosis, % 7.4 ± 1.1 7.4 ± 1.2 0.389
Most recent HbA1c, % 6.8 ± 0.9 6.8 ± 0.7 0.101
HbA1c change from diagnosis, % -0.5 (-6.9, 7.5) -0.4 (-8.5, 1.5) 0.189
Proportion with most recent HbA1c ≥7% 31 32 0.600
FBG closest to diagnosis, mmol/L 9.1 ± 2.8 9.0 ± 2.6 0.505
Most recent FBG, mmol/L 7.1 ± 1.9 7.0 ± 2.0 0.824
Proportion with most recent FBG ≥7 mmol/L 21 20 0.380
Other characteristics and comorbidities
Serum creatinine, μmol/L 85.7 ± 25.5 97.7 ± 31.7 < 0.001
LDL-cholesterol, mmol/L 2.7 ± 2.3 2.5 ± 1.3 0.019
HDL-cholesterol, mmol/L 1.3 ± 0.5 1.4 ± 0.5 0.084
Triglycerides, mmol/L 2.1 ± 1.3 1.7 ± 0.8 < 0.001
Cardiovascular conditions 5.2 18.3 < 0.001
Ischemic heart disease 3.5 9.4 < 0.001
Myocardial infarction 1.8 4.4 < 0.001
Peripheral vascular disease 0.9 2.1 0.027
Stroke 0.6 3.9 < 0.001
Microvascular complications 4.3 15.4 < 0.001
Neuropathy 0.7 1.3 0.184
Retinopathy 1.1 2.0 0.105
Renal disease 2.8 13.2 < 0.001
Total number of medications 2 (0, 3) 3 (1, 6) < 0.001
Patient’s living situation
Living with spouse/other family member/alone 98.8 89.1 < 0.001
Data are expressed as mean ± standard deviation, frequency (%), or median (interquartile range).
FBG = fasting blood glucose
*Time from first diagnosis of type 2 diabetes mellitus to survey date
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hyperglycaemic agents and Comorbidities and polyphar-
macy were selected more frequently by GPs as reasons for
non-treatment of older patients. The individual reasons
with significant between-group differences appeared to be
focused on issues related to safety (e.g., risk of side effects
or drug-drug interactions), disease or medication burdens
for patients and cognitive or physical function of the
patient. Although not assessed for age-related differences,
similar reasons have been provided by physicians for their
patients not receiving action in diabetes treatment despite
having elevated HbA1c [12]. Diabetes therapies that have
demonstrated efficacy and safety in patients, especially
older patients, may allay some of these concerns raised by
GPs. Furthermore, GPs in the present study set a higher
HbA1c threshold for initiating treatment in older patients.
These results are consistent with previous studies that
have shown that older patients with newly diagnosed type
Table 2 All reasons selected by general practitioners for non-treatment of patients with type 2 diabetes mellitus
Reasons, n (%) Patients
< 65 years
n = 1, 023
Patients
≥65 years
n = 1, 005
p-value
Mild Hyperglycaemia 897 (87.7) 866 (86.2) 0.323
HbA1c value stable, drug therapy not necessary 278 (27.2) 264 (26.3) 0.652
HbA1c value close to NICE recommended threshold 316 (30.9) 326 (32.4) 0.474
Blood glucose values under control with diet and exercise 301 (29.4) 330 (32.8) 0.103
Factors Related to Antihyperglycaemic Agents 386 (37.7) 463 (46.1) < 0.001
May cause hypoglycaemia 176 (17.2) 250 (24.9) < 0.001
May cause fluid retention 67 (6.6) 98 (9.8) 0.009
May cause weight gain 173 (16.9) 157 (15.6) 0.435
May cause gastrointestinal side effects 203 (19.8) 200 (19.9) 0.999
May increase risk of fracture 45 (4.4) 68 (6.8) 0.026
May increase cardiovascular risk 49 (4.8) 68 (6.8) 0.057
May increase risk of lactic acidosis 78 (7.6) 96 (9.6) 0.132
Uncertainty how to dose certain drug 26 (2.5) 25 (2.5) 0.999
Not clear if several agents are safe 30 (2.9) 34 (3.4) 0.612
Efficacy of agents not clear 30 (2.9) 24 (2.4) 0.492
Safety of agents not clear 34 (3.3) 30 (3.0) 0.704
Primary Care Trust cost concerns 24 (2.4) 26 (2.6) 0.776
Cognitive burden of therapy administration too high for patient 66 (6.5) 121 (12.0) < 0.001
Cognitive burden of monitoring glucose too high for patient 48 (4.7) 87 (8.7) < 0.001
Difficulties/ability to change patient’s lifestyle 118 (11.5) 119 (11.8) 0.836
Risk of non-compliance (not related to side effects) 115 (11.2) 132 (13.1) 0.198
Risk of non-compliance due to side effects 80 (7.8) 115 (11.4) 0.007
Lack of monitoring due to physical limitations (e.g., dexterity) 32 (3.1) 82 (8.2) < 0.001
Comorbidities and Polypharmacy 192 (18.8) 333 (33.1) < 0.001
Patient has other severe disease(s) 69 (6.7) 172 (17.1) < 0.001
Medical diabetes treatment is contraindicated 27 (2.6) 38 (3.8) 0.166
Patient is taking several other medications already 108 (10.6) 216 (21.5) < 0.001
Risk of side effects (related to polypharmacy) 124 (12.1) 191 (19.0) < 0.001
Risk of drug-drug interactions (related to polypharmacy) 60 (5.9) 100 (10.0) < 0.001
Patient-Related Reasons 443 (43.2) 416 (41.4) 0.419
Patient denial/anger/depression related to diabetes diagnosis 120 (11.7) 108 (10.8) 0.527
Patient’s follow-up visit is overdue 92 (9.0) 64 (6.4) 0.030
Patient does not want to take (additional) medication 325 (31.8) 305 (30.4) 0.502
Fear of hypoglycaemia 71 (6.9) 93 (9.3) 0.061
Fear of weight gain 112 (11.0) 78 (7.8) 0.015
Fear to change from diet/exercise to oral agents 100 (9.8) 88 (8.8) 0.445
Fear to change from diet/exercise to insulin 54 (5.3) 53 (5.3) 0.999
Patient has physical difficulty taking medication 29 (2.8) 44 (4.4) 0.073
Drug therapy decreases quality of life 61 (6.0) 76 (7.6) 0.158
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caemic therapy [8,9]. The reasons identified in the present
study may help explain the clinical inertia or inequality of
health care observed in previous studies. It is understand-
able to focus on issues related to safety and functional
capacity when considering diabetes treatments and man-
agement in older patients, especially frail patients [14].
However, in the present study, a majority of older patients
lived independently. Furthermore, given that older patients
have higher prevalence of comorbidities, failure to treat or
delays in diabetes treatment for this population may have
greater health implications than for younger patients.
There are many factors that influence the treatment of
patients with type 2 diabetes mellitus. In a focus group set-
ting with family physicians, Brown et al. [15] identified
patient-, physician- and systemic-related factors that were
considered barriers and facilitators to the management of
patients with type 2 diabetes mellitus. For patient factors,
physicians felt that many patients with type 2 diabetes
mellitus failed to recognise the seriousness of their disease
due its asymptomatic nature. Education was seen as both
a barrier and facilitator to disease management. Physicians
indicated that early education led to better outcomes for
their patients. Conversely, physicians felt overwhelmed
with all of the different treatment guidelines for their dia-
betic patients and associated comorbid conditions [15]. In
another study, reasons of GPs for not prescribing lipid-
lowering agents in patients with type 2 diabetes mellitus
were divided into patient- and physician-related factors
[16]. Patient-related factors included compliance or refusal
to take prescribed medication due to expected or per-
ceived side effects. Physician reasons were related to proxi-
mity to treatment targets, perceived lack of benefits in
patients with short life expectancy and expected compli-
ance problems with their patients [16]. In the present
study, risk of non-compliance was selected by up to 13%
of GPs as a reason for non-treatment. Overall, these and
the present results demonstrate that diverse factors influ-
ence the GP’s decision to initiate treatment in patients
with type 2 diabetes mellitus.
The following limitations should be considered when
interpreting the results of this study. Observed trends
pertain to GPs and might not be generalisable to endocri-
nologists, diabetes, or GPs who do not treat many
patients with type 2 diabetes mellitus. A selection bias
may have occurred as the GPs needed to meet specific
criteria in order to be eligible to participate, which may
have limited the participating GPs to those who had a
greater focus on diabetes care. Other reasons not identi-
fied may influence GPs for not initiating therapy (e.g., life
expectancy, overall quality of life, or recent clinical find-
ings). All physician-reported laboratory measures closest
to diagnosis were included in the analysis regardless of
the timing of measurement. Although GPs provided the
clinical data of patients who met specific criteria, the GPs
self selected the patients from their practices. GPs
entered select patient data in the online form and com-
pleteness of the form was assessed. Validation of data
Figure 1 The distribution of the most recent HbA1c level by GP’s first-ranked reason for non-treatment. AHAs = antihyperglycaemic
agents.
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the data (e.g., edit checks).
Conclusions
GPs selected reasons related mainly to Mild hyperglycae-
mia for non-treatment with antihyperglycaemic agents
for their untreated patients with newly diagnosed type 2
diabetes mellitus, despite nearly one-third of these
patients having their most recent HbA1c ≥7%. In addi-
tion, the survey findings suggest that issues related to
safety of antihyperglycaemic agents, burden to the
patients, and cognitive or physical function of the patient
influence the non-treatment of older patients with type 2
diabetes mellitus.
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